Back to User profile » Dr Stephan Herbertz

Paper published by Dr Stephan Herbertz:


Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, Slapak CA, Lahn MM

Drug Design, Development and Therapy 2015, 9:4479-4499

Published Date: 10 August 2015